Oxaliplatin Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-171

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 68083-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin-image1 (Oxaliplatin Image1)

A two-day chemotherapy treatment schedule diagram showing administrations of Leucovorin 200 mg/m², 5-FU bolus 400 mg/m² over 2 to 4 minutes, 5-FU infusion 600 mg/m², and Oxaliplatin injection 85 mg/m² on Day 1, followed by similar drug administrations on Day 2 with specified time intervals including 2-hour and 22-hour durations.*

FDA Label Image

Oxaliplatin-image2 (Oxaliplatin Image2)

Chemical structure of Oxaliplatin showing platinum (Pt) coordinated with a cyclohexane ring bearing two amine (NH2) groups and oxalate ligands.*

FDA Label Image

Oxaliplatin-image3 (Oxaliplatin Image3)

A Kaplan-Meier curve chart showing disease-free survival (DFS) probabilities over 72 months for two treatment arms labeled FOLFOX4 and LV5FU2. The chart includes hazard ratio, confidence interval, and number of events with percentages for each arm. Patient counts at risk are listed below the x-axis at multiple time points.*

FDA Label Image

Oxaliplatin-image4 (Oxaliplatin Image4)

A Kaplan-Meier survival curve chart displaying Disease-Free Survival (DFS) probability over time in months for patients with Stage III disease. It compares treatment arms FOLFOX4 (DUKES C) and LV5FU2 (DUKES C). The graph includes a hazard ratio with 95% confidence interval and a p-value from a Logrank test, illustrating survival differences between treatments over a 72-month period.*

FDA Label Image

Oxaliplatin-image5 (Oxaliplatin Image5)

A Kaplan-Meier survival curve depicting overall survival over 24 months by treatment arm. The graph compares the percentage of patients surviving over time for three groups: Oxaliplatin for Injection + 5-FU/LV, Oxaliplatin for Injection + Irinotecan, and Irinotecan + 5-FU/LV. Median survival times are listed for each group alongside the curves. A statistical significance marker (P < 0.0001) is noted.*

FDA Label Image

Image6 (Oxaliplatin Image6)

Label for Oxaliplatin for Injection, USP 50 mg/vial, a cytotoxic agent in sterile lyophilized powder form for intravenous use. The single-dose vial is preservative-free and requires reconstitution and dilution before use. Manufactured by Gland Pharma Limited in Visakhapatnam, India. Storage guidelines and warnings against reconstitution with sodium chloride or chloride-containing solutions are noted.*

FDA Label Image

Image7 (Oxaliplatin Image7)

Oxaliplatin 50 mg/Vial for Injection, USP, lyophilized powder for solution, in a single-dose vial. Label states it is a cytotoxic agent for intravenous use only, preservative free, and must be reconstituted and diluted before use. Manufactured by Gland Pharma Limited, Visakhapatnam, India. Packaging includes storage and reconstitution instructions, caution against use with sodium chloride solutions, lot and expiry placeholders, and a barcode.*

FDA Label Image

Image8 (Oxaliplatin Image8)

Oxaliplatin for Injection, USP 100 mg per vial lyophilized powder for solution labeled for intravenous use. The single-dose vial is sterile and preservative-free, made by Gland Pharma Limited. The label includes handling instructions, storage conditions (20°-25°C), and warnings against reconstitution with sodium chloride/chloride solutions. It also notes inactive ingredient lactose monohydrate 900 mg and includes a barcode and lot and expiration date areas.*

FDA Label Image

Image9 (Oxaliplatin Image9)

Oxaliplatin for Injection, USP 100 mg/Vial sterile lyophilized powder for solution, labeled as a cytotoxic agent for intravenous use only. The single-dose vial is preservative-free and must be reconstituted and diluted before use. The packaging includes warnings against reconstitution with sodium chloride or chloride-containing solutions. Manufactured by Gland Pharma Limited, Visakhapatnam, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.